S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price & News

$6.42
-0.35 (-5.17%)
(As of 10/3/2023 ET)
Compare
Today's Range
$6.20
$6.77
50-Day Range
$6.42
$7.92
52-Week Range
$6.20
$14.50
Volume
2.69 million shs
Average Volume
2.77 million shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.63

BioCryst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.2% Upside
$13.63 Price Target
Short Interest
Bearish
22.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.57mentions of BioCryst Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

362nd out of 966 stocks

Biological Products, Except Diagnostic Industry

48th out of 144 stocks


BCRX stock logo

About BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Price History

BCRX Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
BioCryst (BCRX) was upgraded to a Buy Rating at RBC Capital
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
H.C. Wainwright Keeps Their Buy Rating on BioCryst (BCRX)
BioCryst Pharmaceuticals Q2 2023 Earnings Preview
See More Headlines
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BCRX Company Calendar

Last Earnings
8/03/2023
Today
10/03/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BCRX
CUSIP
09058V10
Employees
531
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$13.63
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+112.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-247,120,000.00
Pretax Margin
-78.17%

Debt

Sales & Book Value

Annual Sales
$270.83 million
Book Value
($1.58) per share

Miscellaneous

Free Float
181,156,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
1.85

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jon P. StonehouseMr. Jon P. Stonehouse (Age 62)
    CEO, Pres & Exec. Director
    Comp: $1.15M
  • Mr. Anthony J. DoyleMr. Anthony J. Doyle (Age 43)
    Sr. VP & CFO
    Comp: $726.42k
  • Ms. Alane P. BarnesMs. Alane P. Barnes (Age 57)
    Sr. VP, Chief Legal Officer & Corp. Sec.
    Comp: $655.33k
  • Dr. William P. Sheridan MBBS (Age 68)
    Chief Devel. Officer
    Comp: $784.09k
  • Dr. Yarlagadda S. BabuDr. Yarlagadda S. Babu (Age 70)
    Chief Discovery Officer
    Comp: $691.45k
  • Dr. Helen M. Thackray FAAP (Age 55)
    M.D., Chief R&D Officer
    Comp: $844k
  • Mr. Charles K. Gayer (Age 52)
    Sr. VP & Chief Commercial Officer
    Comp: $643.43k
  • Mr. Michael L. Jones (Age 53)
    Exec. Director of Fin. & Principal Accounting Officer
  • Mr. John D. Bluth (Age 50)
    Chief Communications Officer
  • Ms. Stephanie Angelini
    Chief People Officer













BCRX Stock - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings
or view top-rated stocks.

What is BioCryst Pharmaceuticals' stock price forecast for 2023?

7 analysts have issued twelve-month price targets for BioCryst Pharmaceuticals' stock. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they anticipate the company's share price to reach $13.63 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price.
View analysts price targets for BCRX
or view top-rated stocks among Wall Street analysts.

How have BCRX shares performed in 2023?

BioCryst Pharmaceuticals' stock was trading at $11.48 on January 1st, 2023. Since then, BCRX shares have decreased by 44.1% and is now trading at $6.42.
View the best growth stocks for 2023 here
.

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our BCRX earnings forecast
.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. The biotechnology company had revenue of $81.01 million for the quarter, compared to the consensus estimate of $81.42 million. BioCryst Pharmaceuticals's quarterly revenue was up 24.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) EPS.

What ETFs hold BioCryst Pharmaceuticals' stock?
What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?
What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $6.42.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.22 billion and generates $270.83 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

The company employs 531 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314.

This page (NASDAQ:BCRX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -